Wilate

Wilate is a human coagulation factor VIII and von Willebrand factor concentrate used for managing bleeding disorders. This intravenous therapy supports hemostasis in conditions like hemophilia A and von Willebrand disease. Suitable for patients requiring factor replacement.

Wilate provides human coagulation factor VIII and von Willebrand factor to support blood clotting. It is used to prevent or control bleeding episodes in patients with hemophilia A or von Willebrand disease. The therapy helps maintain normal clotting function during surgeries or injuries.

Wilate works by replacing missing or deficient clotting factors in the bloodstream. This helps restore the body’s natural ability to stop bleeding. Patients may notice improved clotting after administration, reducing the risk of prolonged bleeding.

Wilate should be handled with care to avoid contamination or infection. It is administered intravenously under medical supervision to ensure proper dosing and monitoring. Patients should inform healthcare providers of any allergies or prior reactions to blood products.

Wilate may interact with other medications affecting blood clotting, such as anticoagulants or antiplatelet drugs. Patients should disclose all current medications to their healthcare provider. Alcohol and certain herbal supplements may also influence clotting function.